首页> 美国卫生研究院文献>Oncotarget >Fluorescent humanized anti-CEA antibody specifically labels metastatic pancreatic cancer in a patient-derived orthotopic xenograft (PDOX) mouse model
【2h】

Fluorescent humanized anti-CEA antibody specifically labels metastatic pancreatic cancer in a patient-derived orthotopic xenograft (PDOX) mouse model

机译:荧光人源化抗CEA抗体在源自患者的原位异种移植(PDOX)小鼠模型中特异性标记转移性胰腺癌

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pancreatic cancer is a highly lethal disease in part due to incomplete tumor resection. Targeting by tumor-specific antibodies conjugated with a fluorescent label can result in selective labeling of cancer in vivo for surgical navigation. In the present study, we describe a patient-derived orthotopic xenograft model of pancreatic cancer that recapitulated the disease on a gross and microscopic level, along with physiologic clinical manifestations. We additionally show that the use of an anti-CEA antibody conjugated to the near-infrared (NIR) fluorescent dye, IRDye800CW, can selectively highlight the pancreatic cancer and its metastases in this model with a tumor-to-background ratio of 3.5 (SEM 0.9). The present results demonstrate the clinical potential of this labeling technique for fluorescence-guided surgery of pancreatic cancer.
机译:胰腺癌是高度致死性疾病,部分原因是肿瘤切除不完全。通过与荧光标记物偶联的肿瘤特异性抗体的靶向作用,可导致体内选择性标记癌症以进行手术导航。在本研究中,我们描述了胰腺癌患者的原位异种移植模型,该模型概括了疾病的总体和微观水平,以及生理学临床表现。我们还显示,使用与近红外(NIR)荧光染料IRDye800CW偶联的抗CEA抗体可以在该模型中选择性地突出显示胰腺癌及其转移,肿瘤与背景的比率为3.5(SEM 0.9)。本结果证明了这种标记技术在胰腺癌的荧光引导手术中的临床潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号